Kelly Suchman
Kelly Suchman has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Arvind Julius Trindade
Division of Gastroenterology, Rutgers University School of Medicine, New Brunswick, United States
2 shared publications - Diana Wee
Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, New Hyde Park
2 shared publications - Ari Grinspan
Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
1 shared publication - Ben L. Da
Division of Liver Diseases and Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, United States
1 shared publication - Danielle Aronsky
Internal Medicine, Northwell Health, Long Island Jewish Medical Center, New Hyde Park, USA
1 shared publication - Jobin Philipose
Gastroenterology and Hepatology, Northwell Health-Staten Island University Hospital, Staten Island, USA
1 shared publication
Latest Publications
- 20 May 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 76 (4) , E78-E79
Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC
- 20 May 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 76 (4) , E78-E79
Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC
- Open Access
- 21 February 2022
- Published by Springer Nature in Cureus
- Vol. 14 (2) , e22452
A Case of Acute Liver Failure in a Patient on Isoniazid Prophylaxis for Latent Tuberculosis
Isoniazid (INH) is widely used for latent Mycobacterium tuberculosis despite the known risk of liver injury, with severe hepatitis occurring in up to 1% of patients. We report a patient who presented with two weeks of anorexia, nausea, and jaundice following six months of INH monotherapy for latent tuberculosis (TB). After other causes of liver injury were ruled out, she underwent a liver biopsy showing submassive necrosis, hepatocellular dropout, and lobular inflammation with no evidence of fibrosis. She was also found to have acute portal hypertension. She was diagnosed with drug-induced liver injury (DILI) and was treated with n-acetyl cysteine (NAC), ursodiol, and vitamin K. She recovered without the need for a liver transplant. This case supports the need for monitoring of liver tests in high-risk individuals on INH therapy to reduce the risk of hepatotoxicity.
- 21 February 2022
- Published by Springer Nature in Cureus
- Vol. 14 (2) , e22452
Open AccessA Case of Acute Liver Failure in a Patient on Isoniazid Prophylaxis for Latent Tuberculosis
Isoniazid (INH) is widely used for latent Mycobacterium tuberculosis despite the known risk of liver injury, with severe hepatitis occurring in up to 1% of patients. We report a patient who presented with two weeks of anorexia, nausea, and jaundice following six months of INH monotherapy for latent tuberculosis (TB). After other causes of liver injury were ruled out, she underwent a liver biopsy showing submassive necrosis, hepatocellular dropout, and lobular inflammation with no evidence of fibrosis. She was also found to have acute portal hypertension. She was diagnosed with drug-induced liver injury (DILI) and was treated with n-acetyl cysteine (NAC), ursodiol, and vitamin K. She recovered without the need for a liver transplant. This case supports the need for monitoring of liver tests in high-risk individuals on INH therapy to reduce the risk of hepatotoxicity.
- 9 January 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (10) , 4866-4873
Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort
Background Immunocompromised patients are particularly vulnerable to Clostridioides difficile infection (CDI), hospitalizations and recurrences. Studies have shown that fecal microbiota transplant (FMT) is safe and effective in immunocompromised patients. Aims To examine the outcomes of FMT for CDI in a diverse cohort of immunocompromised patients stratified by medication class. Methods We performed a retrospective, long-term follow-up study of FMT in immunocompromised patients, including those undergoing chemotherapy, with inflammatory bowel disease (IBD) on immunomodulators, prior solid organ transplant on immunosuppressants, on chronic steroids 20 mg/day or higher for a minimum of three months, or HIV positive. Primary outcomes included adjusted primary cure rate within 8 weeks, as well as rates of non-response, recurrences, relapses and adverse events. Secondary outcomes included adjusted overall cure rate. Primary cure rate was defined as patients not requiring repeat CDI treatment within 8 weeks after index FMT, and overall cure rate was defined as resolution of CDI symptoms after index FMT or second FMT. Results Our cohort included 77 immunosuppressed patients (53.2% female, median age 39.1 years, range 7–95 years). The majority of our cohort were IBD patients on biologics (62.3%). Adjusting for colectomies and deaths, our primary and overall cure rates were 85.1% and 86.5%, respectively. Twelve patients received FMT for severe or fulminant CDI with a 3-month survival rate of 91.7%. 11.7% of patients experienced serious adverse events following FMT. Conclusions Our study supports the efficacy and safety of FMT in immunocompromised patients, though future research is needed to further ascertain the potential effects of immunosuppression on FMT outcomes.
- 9 January 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (10) , 4866-4873
Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort
Background Immunocompromised patients are particularly vulnerable to Clostridioides difficile infection (CDI), hospitalizations and recurrences. Studies have shown that fecal microbiota transplant (FMT) is safe and effective in immunocompromised patients. Aims To examine the outcomes of FMT for CDI in a diverse cohort of immunocompromised patients stratified by medication class. Methods We performed a retrospective, long-term follow-up study of FMT in immunocompromised patients, including those undergoing chemotherapy, with inflammatory bowel disease (IBD) on immunomodulators, prior solid organ transplant on immunosuppressants, on chronic steroids 20 mg/day or higher for a minimum of three months, or HIV positive. Primary outcomes included adjusted primary cure rate within 8 weeks, as well as rates of non-response, recurrences, relapses and adverse events. Secondary outcomes included adjusted overall cure rate. Primary cure rate was defined as patients not requiring repeat CDI treatment within 8 weeks after index FMT, and overall cure rate was defined as resolution of CDI symptoms after index FMT or second FMT. Results Our cohort included 77 immunosuppressed patients (53.2% female, median age 39.1 years, range 7–95 years). The majority of our cohort were IBD patients on biologics (62.3%). Adjusting for colectomies and deaths, our primary and overall cure rates were 85.1% and 86.5%, respectively. Twelve patients received FMT for severe or fulminant CDI with a 3-month survival rate of 91.7%. 11.7% of patients experienced serious adverse events following FMT. Conclusions Our study supports the efficacy and safety of FMT in immunocompromised patients, though future research is needed to further ascertain the potential effects of immunosuppression on FMT outcomes.
- Open Access
- 1 January 2021
- Published by Elsevier in Techniques and Innovations in Gastrointestinal Endoscopy
- Vol. 23 (3) , 285-287
Patient Centered Outcomes Regarding Telemedicine Prior to Endoscopy During the Coronavirus Disease 2019 Pandemic
- 1 January 2021
- Published by Elsevier in Techniques and Innovations in Gastrointestinal Endoscopy
- Vol. 23 (3) , 285-287
Open AccessPatient Centered Outcomes Regarding Telemedicine Prior to Endoscopy During the Coronavirus Disease 2019 Pandemic
- 1 January 2021
- Published by Elsevier in Pancreatology
- Vol. 21 (1) , 31-33
Acute pancreatitis in children hospitalized with COVID-19
- 1 January 2021
- Published by Elsevier in Pancreatology
- Vol. 21 (1) , 31-33
Acute pancreatitis in children hospitalized with COVID-19